Description: TRODELVY® (sacituzumab govitecan-hziy) | Learn about mechanism of action, safety, trial information, dosing, and support services. See full Prescribing Information, including BOXED WARNING.
For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease
See more data and study design below
In the Phase 3 ASCENT study, TRODELVY demonstrated a proven survival benefit versus single-agent chemotherapy (4.8 versus 1.7 months median PFS and 11.8 versus 6.9 months median OS P <0.0001, n=267 versus n=262) 1,2